Karius

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.

lucence

Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment. Headquartered in Palo Alto and Singapore, Lucence supplies personalized cancer care services through twin CLIA-licensed laboratories in the United States and Singapore. For more information, visit www.lucence.com.

AlloVir

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products Find AGTC on YouTube at goo.gl/sMdJqX.

ActiGraph

ActiGraph is pioneering the digital transformation of clinical research. We provide end-to-end digital health technology (DHT) solutions by integrating and operationalizing the best wearables, software, and algorithms to generate reliable evidence and get the right treatments to the right patients, faster. ActiGraph’s medical-grade wearable technology platform has been used to capture real-world, continuous digital measures of sleep, activity, and mobility for nearly 250 industry-sponsored clinical trials and thousands of academic research and public health studies. Appearing in over 22,000 published scientific papers to date, ActiGraph is the most experienced and trusted wearable technology partner in the industry.